Filtered By:
Cancer: Acute Myeloid Leukemia
Procedure: Transplants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1187 results found since Jan 2013.
Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax
In this study, prior chemotherapy/allo-SCT and cytogenetic risk were associated with VEN treatment outcomes.PMID:37728705 | DOI:10.1007/s12185-023-03664-1
Source: International Journal of Hematology - September 20, 2023 Category: Hematology Authors: Ryujiro Hara Shinichiro Machida Norisato Hashimoto Daisuke Ogiya Hidetsugu Kawai Shohei Kawakami Sawako Shiraiwa Makoto Onizuka Yoshiaki Ogawa Hiroshi Kawada Kiyoshi Ando Source Type: research
Acute Myeloid Leukemia Causes T Cell Exhaustion and Depletion in a Humanized Graft-versus-Leukemia Model
J Immunol. 2023 Sep 15:ji2300111. doi: 10.4049/jimmunol.2300111. Online ahead of print.ABSTRACTAllogeneic hematopoietic stem cell transplantation (alloSCT) is, in many clinical settings, the only curative treatment for acute myeloid leukemia (AML). The clinical benefit of alloSCT greatly relies on the graft-versus-leukemia (GVL) effect. However, AML relapse remains the top cause of posttransplant death; this highlights the urgent need to enhance GVL. Studies of human GVL have been hindered by the lack of optimal clinically relevant models. In this article, we report, the successful establishment of a novel (to our knowledg...
Source: Journal of Immunology - September 15, 2023 Category: Allergy & Immunology Authors: Bei Jia Chenchen Zhao Kentaro Minagawa Hiroko Shike David F Claxton W Christopher Ehmann Witold B Rybka Shin Mineishi Ming Wang Todd D Schell K Sandeep Prabhu Robert F Paulson Yi Zhang Leonard D Shultz Hong Zheng Source Type: research
Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia
Cell Transplant. 2023 Jan-Dec;32:9636897231198178. doi: 10.1177/09636897231198178.ABSTRACTRefractory acute myeloid leukemia (AML), defined as failure of two cycles of induction therapy at diagnosis or of one cycle at relapse, represents a subgroup with poor outcomes. Haploidentical natural killer cell (NK) therapy is a strategy that is being explored in refractory malignancies. Historically, at our center, patients with refractory AML have been treated with cytoreductive therapy (fludarabine + cytosine + granulocyte colony-stimulating factor ± idarubicin or mitoxantrone + etoposide) followed by 1-week rest and then reduce...
Source: Cell Transplantation - September 14, 2023 Category: Cytology Authors: Uday Kulkarni Arun Kumar Arunachalam Hamenth Kumar Palani Reeshma Radhakrishnan Nair Nithya Balasundaram Arvind Venkatraman Anu Korula Sushil Selvarajan Sharon Lionel Poonkuzhali Balasubramanian Madhavi Maddali Aby Abraham Biju George Vikram Mathews Source Type: research
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients
Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidit...
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Amandeep Salhotra Paul Koller Source Type: research
Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
CONCLUSION: This study suggests that Treo/Flu conditioning may be an alternative to Bu/Flu regimen in elderly patients with high-risk who are not suitable for standard conditioning.PMID:37698206 | PMC:PMC10497350 | DOI:10.3346/jkms.2023.38.e281
Source: J Korean Med Sci - September 12, 2023 Category: General Medicine Authors: Se Hyung Kim Young Sok Ji Jina Yun Seong Hyeok Choi Sung Hee Lim Chan Kyu Kim Seong Kyu Park Source Type: research
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study
Lancet Haematol. 2023 Sep 6:S2352-3026(23)00212-0. doi: 10.1016/S2352-3026(23)00212-0. Online ahead of print.ABSTRACTBACKGROUND: Second primary malignancies (SPMs) are known complications after chemotherapy, but the risk is not well characterised for patients with lymphoma treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the rate of SPMs in this population relative to matched control individuals from the general population.METHODS: In this retrospective, population-based cohort study, patients aged 18 years or older with an aggressive lymphoma who r...
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Trine Trab Joachim Baech Lasse Hjort Jakobsen Simon Husby Marianne Tang Severinsen Sandra Eloranta Jette S G ørløv Judit M J ørgensen Sif Gudbrandsdottir Thomas Stauffer Larsen Peter Brown Kirsten Gr ønbæk Karin E Smedby Tarec C El-Galaly Source Type: research
